Drug intelligence / Profile preview

inclocibart

Development stage: Phase 2
Lead developer: Bayer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Inclocibart is a humanized IgG4 lambda1 monoclonal antibody directed against alpha-2-antiplasmin (SERPINF2), the principal physiological inhibitor of plasmin in the fibrinolytic system. By binding SERPINF2, inclocibart is designed to inhibit alpha-2-antiplasmin activity, thereby enhancing endogenous plasmin-mediated fibrin degradation and promoting fibrinolysis.[1][3][7][15] This agent is being investigated as a targeted biologic to modulate thrombosis and fibrinolysis pathways, although detailed clinical development, indications, and sponsoring company information have not yet been broadly disclosed.

Other names: inclocibart

Targets

SERPINF2 (Alpha-2-antiplasmin)

Beyond the preview

Go deeper on inclocibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inclocibart.

Explore the full profile